OTC Proposals Need To Protect End-Users Better
Proposals to regulate over-the-counter derivatives do not go far enough in exempting corporate OTC end-users from margining or capital provisions, according to Jiro Okochi, ceo and co-founder of Reval, a derivative risk management provider.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: